Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms

• ClinicalTrials.gov Identifier: NCT04727424
• Recruitment Status: Recruiting
• First Posted: January 27, 2021
• Last Update Posted: July 7, 2022
• Sponsor: Cardresearch
• Collaborators: Cytel Inc.; McMaster University; Fastgrants; Eiger BioPharmaceuticals; RainWater Foundation
• Information provided by (Responsible Party): Cardresearch

Study Description

Brief Summary:

The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in certain subgroups of patients. To date, no treatment has been shown to be effective in patients with early-onset disease and mild symptoms. Experimental studies have demonstrated a potential anti-inflammatory role of Fluvoxamine, Fluoxetine, Budesonide and Pegilatrd Interferon Lambda in SARS-CoV-2 infections and observational studies have suggested a reduced complications in patients with COVID-19 disease.

Condition or disease	Intervention/treatment	Phase
Covid19; SARS-Associated Coronavirus	Drug: Fluvoxamine Maleate 100 MG [Luvox]; Drug: Budesonide Powder; Drug: Placebo (mild disease); Drug: Peginterferon Lambda-1a; Drug: Fluoxetine 20 MG	Phase 3

Detailed Description:

In December 2019 a series of viral pneumonia cases were reported in the city of Wuhan, China and a new subtype of coronavirus has been identified as the causative agent of this condition. On February 11, 2000 the disease has been characterized as COVID-19 and on March 11 the World Health Organization (WHO) declared a state of worldwide pandemic. On January 25, 2021 there are 98,794,942 cases and 2,124,193 documented deaths (global case-fatality ratio of 2.15%).

To date, no early treatment has been identified as effective in combating this disease which has been identified as with high morbidity and mortality. Epidemiological data suggest that despite development of vaccines we will have hundreds od thousands of cases in the next two years.

Thus, we propose the prospective, double-blinded, randomized evaluation of potential therapies against SARS-CoV2 and some clinical evidence derived from observational studies on reducing complications if used early on the disease, before inflammatory cascade is fully activated.

Important considerations on TOGETHER Trial:

1. Vaccinated patients were proposed to be an exclusion criteria on amendment 3 which was received final National Ethics Committee (CONEP) decision letter number 4.747.755_E3 dated June 01, 2021. We evaluated vaccination data and outcomes on two large cities involving 150.000 individuals and based on these results we submitted to the IRB a notification request to withdraw the exclusion criteria 4 (vaccination > 14 days) on July 14, 2021, which was granted.
2. The amendment 5 proposed a collaborative partnership with ANTICOV Consortia and incorporating the fluoxetine + budesonide and its active comparator (paracetamol) arms, as per ANTICOV protocol WHO ERC approval version 13.0. These generated data will be analyzed along with ANTICOV fluoxetine + budesonide and paracetamol arms.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 6246 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment

Intervention Model Description

TOGETHER trial is a Multiplatform, adaptive trial started on 20 Jan 2021. this description is as per amendment five with final Brazilian National Ethics Committee final decision letter issued on 27 January 2022.

Patients with mild disease will be screened at primary and secondary care public health services and randomly allocated to one of four treatment arms in a 1:1:1:1 ratio, as per described in detail in approved protocol version 6.0 dated 03 JAN 2022.

1. Fluvoxamine + Budesonide
2. Fluoxetine + Budesonide
3. Peginterferon Lambda
4. Placebo

Patients with SpO2 < 94% will be randomly allocated to one of two arms in a 1: ! ratio:

1. Fluvoxamine
2. Placebo

We will use a centralized random allocation schedule, generated by computer and stratified by site and age.

• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Masking Description

The investigational medical product will be packaged in similar bottles by a third party who will keep the allocation confidential until the end of the study. The bottles will be sealed and identified as "Research Product with no commercial value" and coded. They will be randomly allocated among the participants using a centralized randomization system The research subjects, medical assistance, administrative and health staff will not have access to the contents of the bottles. All arms will have a placebo counterpart with same dose schedule.

All planned Data and Safety Monitoring Board (DSMB) interim analysis will be blinded. If needed a unblinded statistician will be provided if DSMB decides to stop any arm. At the end of the study, or early termination as per DMSB interim analysis plan, the arms will then be identified.

• Primary Purpose: Treatment
• Official Title: A Multicenter, Prospective, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effect of Interferon Lambda 1A, Fluvoxamina + Budesonida, Fluoxetina + Budesonida in Mild COVID-19 and High Risk of Complications
• Actual Study Start Date: January 19, 2021
• Estimated Primary Completion Date: October 1, 2023
• Estimated Study Completion Date: November 1, 2023

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Fluvoxamine Maleate + Budesonide Inhalation powder; Fluvoxamine 100 mg oral tablets: One tablet after randomization (Day 0) followed by 100 mg BID for the following 09 days PLUS Budesonide Inhalation powder 400 mcg capsule: One 400 mcg capsule (inhalation) after randomization (Day 0) followed by 400 mcg BID for the following 09 days	Drug: Budesonide Powder; One Fluvoxamine tablet every 12 hours since randomization through day 09. PLUS 01 Budesonide powder (inhalation) every 12 hours since randomization through day 09.; Other Name: Fluvoxamine Maleate 100 MG [Luvox]
Active Comparator: Fluvoxamine Maleate; Fluvoxamine 100 mg oral tablets: One tablet after randomization (Day 0) followed by 100 mg BID for the following 09 days	Drug: Fluvoxamine Maleate 100 MG [Luvox]; One tablet every 12 hours since randomization through day 09.
Placebo Comparator: Placebo (mild disease); Placebo SC normal saline syringe (single day schedule): Matching syringes containing 0,5 ml normal saline administered by SC route after randomization Day 0 (single dose SC). OR Placebo oral tablets (10-day schedule): Matching tablets started after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule) PLUS Placebo Inhalation Therapy: One dosing (inhalation) right after randomization (Day 0) followed by one dose BID for the following 09 days OR Paracetamol (07-day schedule - active comparator): Paracetamol 500 mg tablets started after randomization using the dosing regimen of 01 tablet BID starting at Rand. Day (Day 0) until end of Day 06 (total of 07 days schedule) OR Placebo oral tablets (10-day schedule for patients with SPO2 < 94%): One tablet after randomization (Day 0) followed by 01 tablet BID for the following 09 days (total of 10 days schedule)	Drug: Placebo (mild disease); Placebo SC normal saline syringe (single day schedule): Matching syringes containing 0,5 ml normal saline administered by SC route after randomization Day 0 (single dose SC). OR Placebo oral tablets (10-day schedule): Matching tablets started after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule) PLUS Placebo Inhalation Therapy: One dosing (inhalation) right after randomization (Day 0) followed by one dose BID for the following 09 days OR Paracetamol (07-day schedule - active comparator): Paracetamol 500 mg tablets started after randomization using the dosing regimen of 01 tablet BID starting at Rand. Day (Day 0) until end of Day 06 (total of 07 days schedule) OR Placebo oral tablets (10-day schedule for patients with SPO2 < 94%): One tablet after randomization (Day 0) followed by 01 tablet BID for the following 09 days (total of 10 days schedule)
Active Comparator: Peginterferon Lambda; Peginterferon Lambda 180 mcg syringe: One syringe of Peginterferon Lambda will be administered by SC route just after randomization (Day 0 - single dose SC administration).	Drug: Peginterferon Lambda-1a; One syringe of 180 mcg of Peginterferon Lambda SC right after randomization Day 0 (single dose SC administration).
Active Comparator: Fluxetine + Budesonide Inhalation powder; Fluoxetine 20 mg oral tablets: Two tablets right after randomization (Day 0) followed by 40 mg MID for the following 06 days PLUS Budesonide Inhalation powder 400 mcg capsule: One 400 mcg capsule (inhalation) right after randomization (Day 0) followed by 400 mcg BID for the following 06 days	Drug: Fluoxetine 20 MG; Two Fluoxetine tablets every day starting just after randomization through day 07. PLUS 01 Budesonide powder (inhalation) every 12 hours since randomization through day 07.

Outcome Measures

Primary Outcome Measures :

1. Rate of fluvoxamine + budesonide, fluoxetine + budesonide, peginterferon Lambda, fluvoxamine in changing the need for emergency care AND observation for more than 06 hours due to the worsening of COVID-19; [ Time Frame: 28 days ]
   Evaluation of emergency visits and observation unit stay > 06 hours
2. Rate of fluvoxamine + budesonide, fluoxetine + budesonide, peginterferon Lambda and fluvoxamine in changing the need for Hospitalization due to COVID-19 progression and related complications, including lower respiratory tract infection (LRTI) [ Time Frame: 28 days ]
   Hospitalization due to COVID-19 progression and related complications
3. Rate of fluvoxamine + budesonide, fluoxetine + budesonide, peginterferon Lambda and fluvoxamine in changing the COVID-19 associated mortality. [ Time Frame: 28 days ]
   Mortality due to COVID-19 associated complications

Secondary Outcome Measures :

1. Change in viral load on day 03 and 07 after randomization (interferon lambda arm) [ Time Frame: Day 3 and Day 7 ]
   Viral load
2. Time to clinical changes (up to 28 days of randomization), defined as greater than 50% symptoms changing in reference to baseline symptoms) [ Time Frame: Randomization through day 28 ]
   time to > 50% clinical symptoms changes as reported on baseline visit (self reported)
3. Time to clinical failure, defined as time to need for hospitalization due to the clinical progression of COVID-19 or associated complications. [ Time Frame: Randomization through day 28 ]
   Time to hospitalization
4. Number of days with respiratory symptoms since randomization [ Time Frame: Randomization through day 28 ]
   Days with symptoms
5. Rate of all-cause hospitalizations [ Time Frame: Randomization through day 28 ]
   All cause hospitalizations
6. Rate of COVID-19 related hospitalizations [ Time Frame: Randomization through day 28 ]
   COVID-19 hospitalizations
7. Number of days on Mechanical Ventilator [ Time Frame: Randomization through day 28 ]
   Number of days on mechanical Ventilator
8. Number of Days on Intensive Care Unit [ Time Frame: Randomization through day 28 ]
   Number of days on Intensive Care Unit
9. Number of days on hospitalizations [ Time Frame: Randomization through day 28 ]
   Number of days on Hospitalization
10. Health and Functioning after COVID-19 disease [ Time Frame: Day 14 and Day 28 ]
    Self evaluation of health functioning post COVID using Promis Global Health Score. Short term scale is a 10 item patient-reported questionnaire using response options as a 5-point and one 11 point rating scale. Higher scores means better global health.
11. WHO ordinal scale for clinical improvement [ Time Frame: Randomization through day 28 ]
    An 8 item Ordinal Scale for clinical status on COVID-19. Higher numbers means worse clinical status.
12. Number of days on respiratory Symptoms [ Time Frame: randomization through day 28 ]
    Number of days on respiratory symptoms
13. Adherence of Study drug [ Time Frame: Randomization through day 14 ]
    Percentage of adherence on Study drug

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Gender Based Eligibility: Yes
• Gender Eligibility Description: Gender will be assumed as patient self-reported
• Accepts Healthy Volunteers: No

Criteria

A - Inclusion Criteria (except fluoxetine + budesonide and paracetamol arms):

1. Patients over 18 years old with the ability to provide free and informed consent
2. Acute Flu-Like symptoms < 07 days.

3. Patients with at least ONE enhancement criteria:

   1. Age > 50 years.
   2. Diabetes mellitus requiring oral medication or insulin.
   3. Systemic arterial hypertension requiring at least 01 oral medication for BP control.
   4. Known cardiovascular diseases (heart failure, congenital heart disease, valvar heart valve disease, coronary artery disease, cardiomyopathies).
   5. Symptomatic lung disease (emphysema, chronic bronchitis).
   6. Symptomatic asthma patients requiring chronic use of agents for control of symptoms.
   7. Fever > 38 C at baseline.
   8. Obesity, defined as BMI> 30 kg / m2 body weight.
   9. Transplanted patients.
   10. Patient with stage IV chronic kidney disease or on dialysis.
   11. Immunosuppressed patients/ using corticosteroid therapy (equivalent to maximum 10 mg of prednisone per day) and/ or immunosuppressive therapy).
   12. Patients with a history of cancer in the last 05 years or undergoing treatment of a current cancer.
   13. Chronic renal disease KDIGO IV or End-Stage Renal Disease on chronic ambulatory renal replacement therapy.
   14. Patients with important limitation of daily activities due to: Dyspnea, chest pain myalgia (limited to 25% of all randomizations).
4. Patient with positive rapid test for SARS-CoV2 antigen performed on occasion of the screening or patient with a positive SARS-CoV2 diagnostic test within 07 days of the onset of symptoms.
5. Willingness to use the proposed investigative treatment and follow the protocol-related procedures foreseen in the research.
6. Specific inclusion criteria for the fluvoxamine arm: Present significant dyspnea, arterial hypotension, severe dehydration or SpO2 between 85 to 93% in room air at admission and medical decision to discharge patient home, with an observation period at ER not exceeding 12 hours.

B - Inclusion criteria for the Fluoxetine + Budesonide combination arm (07 days of treatment - partnership with the "ANTICOV Consortium"):

1. Patients over 18 years of age with the ability to provide free and informed consent.
2. Patients treated at a Basic Health Unit of the Unified Health System (SUS) or patients treated at emergency care units of the SUS or supplementary medicine with an acute clinical condition compatible with COVID 19.

3. Patients over 18 years of age and a history of at least ONE of the following criteria.

   1. Diabetes mellitus, heart disease, chronic kidney disease, chronic obstructive pulmonary disease, cerebrovascular diseases or patients considered to be underweight or overweight according to the investigator's judgment (BMI ≤ 16 or BMI > 25).

      OR

   2. Individuals aged ≥ 60 years without co-morbidities.
4. COVID-19 confirmed by molecular or antigenic test for SARS-CoV-2 within up to 24 hours prior to screening and a maximum of 2 days after sample collection.
5. Viral syndrome with or without pneumonia and arterial O2 saturation > 94%.
6. Signing the Free and Informed Consent Form before any research procedures.
7. Willingness to use the proposed investigational treatment and follow the procedures provided for in the research.

Exclusion Criteria:

1. Diagnostic test for negative SARS-CoV2 associated with acute flu symptoms (patient with a negative test collected early and becomes positive a few days later is eligible, as long as it is < 07 days since the onset of flu symptoms).
2. Patients with an acute respiratory condition compatible with COVID-19 treated in the primary care network and with a decision to be hospitalized.
3. Patients with acute respiratory symptoms due to other causes.
4. Dyspnea secondary to other acute and chronic respiratory causes or infections (eg, decompensated COPD, Acute bronchitis, Pneumonia other than viral, Primary pulmonary arterial hypertension).
5. Patients requiring hospitalization due to COVID-19 or SpO2 ≤ 93%. NOTE: Patients allocated to the fluvoxamine arm alone may be included if SpO2 is below 94%, with no evidence of acute respiratory failure, provided that the attending physician decides to discharge the unit and continue treatment on an outpatient basis.

6. Exclusion criteria applicable to injectable medication arms:

   a. Patients on chronic use of prednisone, prednisolone or other corticosteroids with doses > 10 mg/day equivalent to prednisone.

7. Exclusion criteria applicable to 07-day treatment arms:

   1. Abnormal findings on physical examination: Respiratory rate ≥ 25 sisters; blood pressure < 90/60 mmHg or > 160/100 mmHg; Weight < 45 kg; recent episodes of vomiting within the last 24 hours or recurrent diarrhea or serum potassium below 3.5 mEq/L.
   2. Severe organ damage that requires resuscitation and ongoing treatment.
   3. Chronic corticosteroid use with equivalent prednisone doses of > 40 mg/day
   4. Immunosuppressive treatment in progress
   5. History of known pulmonary arterial hypertension or pulmonary fibrosis
   6. Patients who have received a previous dose of SARS-CoV-2 vaccine
   7. Use of serotonin reuptake inhibitors (all).

8. Exclusion criteria applicable to 10-day treatment arms:

   1. Chronic use of serotonin reuptake inhibitors other than sertraline
   2. Chronic corticosteroid use with equivalent prednisone doses of > 40 mg/day;
9. Continued use of monoamine oxidative inhibitors (MAOI): Phenelzine, Tranylcypromine, Selegiline, Isocarboxazid, moclobemide.
10. Patients with severe psychiatric disorders - schizophrenia, uncontrolled bipolar disorders, major depression with suicidal ideation.
11. Pregnant or breastfeeding patients.
12. History of severe ventricular cardiac arrhythmia (Ventricular tachycardia, recovered ventricular fibrillation patients) or Long QT Syndrome.
13. Known history of decompensated heart failure (NYHA III or IV), recent myocardial infarction (event < 90 days of screening), unstable angina, recent coronary bypass surgery (procedure < 90 days of screening), recent stroke ( event < 90 days from screening), symptomatic carotid disease, or moderate to severe mitral or aortic stenosis.
14. Surgical procedure or hospitalization planned (for other indications) to occur during treatment or up to 5 days after the last dose of study medication.
15. Current daily and/or uncontrolled alcohol consumption, which, in the investigator's view, could compromise participation in the study.
16. History of seizures in the last month or uncontrolled seizures.
17. Clinical history of moderate to severe hepatic impairment or hepatic cirrhosis with Child-Pugh C classification.
18. Patients with known serious degenerative neurological diseases and/or serious mental illnesses as assessed by the investigator.
19. Inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol.
20. Any clinical conditions, including psychiatric conditions, which, in the investigator's view, could prevent the use of research drugs.
21. Known hypersensitivity and/or intolerance to Fluvoxamine, Budesonide, Pegylated Interferon Lambda and Fluoxetine.
22. Use of drugs which have a known interaction with Fluvoxamine, Budesonide, Pegylated Interferon Lambda and Fluoxetine.
23. Inability to use the drugs and formulations provided for in this research.

Contacts and Locations

Contacts

Contact: Gilmar Reis, MD, PhD; +553132416574; administrador@cardresearch.org

Contact: Eduardo Santos, MD, PhD; +553132416574; duduaugusto1@yahoo.com.br

Locations

Brazil

City of Betim; Recruiting

Betim, MG, Brazil, 32550770

Contact: Daniela C Medeiros, MD,PhD

Contact: Tainara S Vieira

Hospital e Maternidade Santa Rita; Recruiting

Contagem, MG, Brazil, 32215000

Contact: Thiago S Ferreira, MD

City of Governador Valadares; Recruiting

Governador Valadares, MG, Brazil, 35010-000

Contact: Adhemar DF Neto, MD, PhD

Contact: Marina L Marques, SC

City of Ibirité; Recruiting

Ibirité, MG, Brazil, 30240528

Contact: Aline Milagres, RN

Contact: Carla Silva, SC hsfapesq@cardresearch.org

City of Nova Lima; Recruiting

Nova Lima, MG, Brazil, 34000000

Contact: Leticia F Costa, RN

Contact: Rosemary M Silva

City of Santa Luzia; Recruiting

Santa Luzia, MG, Brazil, 33105160

Contact: Eduardo Augusto SM Silva, MD, PhD

Contact: Vitoria HS Campos, SC

City of Sete Lagoas; Recruiting

Sete Lagoas, MG, Brazil, 35700-000

Contact: Vinicius A Correa, MD

Contact: Castilho Vitor Quirino, SC vitor-quirino@hotmail.com

CARDRESEARCH - Cardiologia Assistencial e de Pesquisa; Recruiting

Belo Horizonte, Minas Gerais, Brazil, 30150240

Contact: Izabel Silva, SC 553132416574 coordpesq@cardresearch.org

Principal Investigator: Gilmar Reis, MD,PhD

City of Brumadinho; Recruiting

Brumadinho, Minas Gerais, Brazil, 35.460-000

Contact: Eduardo D Calegari, MD

Principal Investigator: Eduardo Calegari, MD

City of Igarapé; Recruiting

Igarapé, Minas Gerais, Brazil, 32900-000

Contact: Luciene B Ribeiro, RN +55313657574

Centro Universitário FIPMOC; Recruiting

Montes Claros, Minas Gerais, Brazil, 39.408-007

Contact: Ana Maria, MD

Principal Investigator: Ana Maria R Nogueira, MD

Sub-Investigator: Ana Paula FG Alvarenga, MD

Universidade Federal de Ouro Preto; Recruiting

Ouro Preto, Minas Gerais, Brazil, 35400000

Contact: Leonardo CM Savassi, MD, PhD leosavassi@gmail.com

Principal Investigator: Leonardo Savassi, MD, PhD

Sponsors and Collaborators

Cardresearch

Cytel Inc.

McMaster University

Fastgrants

Eiger BioPharmaceuticals

RainWater Foundation

Investigators

• Study Chair: Gilmar Reis, MD,PhD.; Cardresearch - Cardiologia Assistencial e de Pesquisa
• Study Director: Edward J Mills, FRCP; McMaster University

More Information

Publications of Results:

Reis G, Dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres AC, Ferreira TS, Dos Santos CVQ, de Souza Campos VH, Nogueira AMR, de Almeida APFG, Callegari ED, de Figueiredo Neto AD, Savassi LCM, Simplicio MIC, Ribeiro LB, Oliveira R, Harari O, Forrest JI, Ruton H, Sprague S, McKay P, Glushchenko AV, Rayner CR, Lenze EJ, Reiersen AM, Guyatt GH, Mills EJ; TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022 Jan;10(1):e42-e51. doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 28. Erratum In: Lancet Glob Health. 2022 Apr;10(4):e481. Lancet Glob Health. 2022 Sep;10(9):e1246.

Reis G, Dos Santos Moreira Silva EA, Medeiros Silva DC, Thabane L, Cruz Milagres A, Ferreira TS, Quirino Dos Santos CV, de Figueiredo Neto AD, Diniz Callegari E, Monteiro Savassi LC, Campos Simplicio MI, Barra Ribeiro L, Oliveira R, Harari O, Bailey H, Forrest JI, Glushchenko A, Sprague S, McKay P, Rayner CR, Ruton H, Guyatt GH, Mills EJ. Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial. Lancet Reg Health Am. 2022 Feb;6:100142. doi: 10.1016/j.lana.2021.100142. Epub 2021 Dec 14.

Reis G, Silva EASM, Silva DCM, Thabane L, Milagres AC, Ferreira TS, Dos Santos CVQ, Campos VHS, Nogueira AMR, de Almeida APFG, Callegari ED, Neto ADF, Savassi LCM, Simplicio MIC, Ribeiro LB, Oliveira R, Harari O, Forrest JI, Ruton H, Sprague S, McKay P, Guo CM, Rowland-Yeo K, Guyatt GH, Boulware DR, Rayner CR, Mills EJ; TOGETHER Investigators. Effect of Early Treatment with Ivermectin among Patients with Covid-19. N Engl J Med. 2022 May 5;386(18):1721-1731. doi: 10.1056/NEJMoa2115869. Epub 2022 Mar 30.

Other Publications:

Rayner CR, Dron L, Park JJH, Decloedt EH, Cotton MF, Niranjan V, Smith PF, Dodds MG, Brown F, Reis G, Wesche D, Mills EJ. Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19. Am J Trop Med Hyg. 2020 Oct;103(4):1364-1366. doi: 10.4269/ajtmh.20-0995.

Park JJH, Mogg R, Smith GE, Nakimuli-Mpungu E, Jehan F, Rayner CR, Condo J, Decloedt EH, Nachega JB, Reis G, Mills EJ. How COVID-19 has fundamentally changed clinical research in global health. Lancet Glob Health. 2021 May;9(5):e711-e720. doi: 10.1016/S2214-109X(20)30542-8.

Forrest JI, Rawat A, Duailibe F, Guo CM, Sprague S, McKay P, Reis G, Mills EJ. Resilient Clinical Trial Infrastructure in Response to the COVID-19 Pandemic: Lessons Learned from the TOGETHER Randomized Platform Clinical Trial. Am J Trop Med Hyg. 2022 Jan 7;106(2):389-393. doi: 10.4269/ajtmh.21-1202.

Reis G, Mills E. Fluvoxamine for the treatment of COVID-19 - Author's reply. Lancet Glob Health. 2022 Mar;10(3):e333. doi: 10.1016/S2214-109X(21)00588-X. No abstract available.

Thorlund K, Sheldrick K, Mills E. Molnupiravir for Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022 Mar 31;386(13):e32. doi: 10.1056/NEJMc2201612. Epub 2022 Mar 16. No abstract available.

Park JJH, Detry MA, Murthy S, Guyatt G, Mills EJ. How to Use and Interpret the Results of a Platform Trial: Users' Guide to the Medical Literature. JAMA. 2022 Jan 4;327(1):67-74. doi: 10.1001/jama.2021.22507.

Jhuti D, Rawat A, Guo CM, Wilson LA, Mills EJ, Forrest JI. Interferon Treatments for SARS-CoV-2: Challenges and Opportunities. Infect Dis Ther. 2022 Jun;11(3):953-972. doi: 10.1007/s40121-022-00633-9. Epub 2022 Apr 21.

Park JJH, Dron L, Mills EJ. Moving forward in clinical research with master protocols. Contemp Clin Trials. 2021 Jul;106:106438. doi: 10.1016/j.cct.2021.106438. Epub 2021 May 14.

Park JJH, Ford N, Xavier D, Ashorn P, Grais RF, Bhutta ZA, Goossens H, Thorlund K, Socias ME, Mills EJ. Randomised trials at the level of the individual. Lancet Glob Health. 2021 May;9(5):e691-e700. doi: 10.1016/S2214-109X(20)30540-4.

Lee Z, Rayner CR, Forrest JI, Nachega JB, Senchaudhuri E, Mills EJ. The Rise and Fall of Hydroxychloroquine for the Treatment and Prevention of COVID-19. Am J Trop Med Hyg. 2021 Jan;104(1):35-38. doi: 10.4269/ajtmh.20-1320.

Dron L, Dillman A, Zoratti MJ, Haggstrom J, Mills EJ, Park JJH. Clinical Trial Data Sharing for COVID-19-Related Research. J Med Internet Res. 2021 Mar 12;23(3):e26718. doi: 10.2196/26718.

Dillman A, Park JJH, Zoratti MJ, Zannat NE, Lee Z, Dron L, Hsu G, Smith G, Khakabimamaghani S, Harari O, Thorlund K, Mills EJ. Reporting and design of randomized controlled trials for COVID-19: A systematic review. Contemp Clin Trials. 2021 Feb;101:106239. doi: 10.1016/j.cct.2020.106239. Epub 2020 Dec 3.

• Responsible Party: Cardresearch
• ClinicalTrials.gov Identifier: NCT04727424
• Other Study ID Numbers: TOGETHER_2
• First Posted: January 27, 2021
• Last Update Posted: July 7, 2022
• Last Verified: January 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: Patient tables and main data.
• Supporting Materials: Statistical Analysis Plan (SAP)
• Time Frame: As of protocol termination
• Access Criteria: Upon request

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Cardresearch:

COVID-19; Randomized study; Fluvoxamine; Peginterferon Lambda; Budesonide; Fluoxetine

Additional relevant MeSH terms:

COVID-19; Severe Acute Respiratory Syndrome; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Budesonide; Fluvoxamine; Fluoxetine; Maleic acid; Anti-Inflammatory Agents; Bronchodilator Agents; Autonomic Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Anti-Asthmatic Agents; Respiratory System Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Selective Serotonin Reuptake Inhibitors